Mackenzie Financial’s Cidara Therapeutics CDTX Stock Holding History

Mackenzie Financial’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,224	Closed	-$270K	–	1481
2025 Q4	$270K	Buy	+1,224	New	+$198K	﹤0.01%	1426
2024 Q2	–	Sell	-1,965	Closed	-$36.1K	–	1552
2024 Q1	$36.1K	Buy	1,965 +702	+56%	+$10.1K	﹤0.01%	1497
2023 Q4	$20.1K	Hold	1,263	–	–	﹤0.01%	1484
2023 Q3	$23.4K	Buy	1,263 +135	+12%	+$2.65K	﹤0.01%	1450
2023 Q2	$25.5K	Buy	+1,128	New	+$26.5K	﹤0.01%	1490

Mackenzie Financial's CDTX Position: Q1 2026 in Review

Mackenzie Financial sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 1,224 shares — an estimated $270K sold.

Mackenzie Financial first reported a position in CDTX in Q2 2023 and held it in 5 quarters. The position peaked at $270K in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Mackenzie Financial reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Mackenzie Financial sold 1,224 Cidara Therapeutics shares in Q1 2026, an estimated $270K.
Mackenzie Financial first reported a position in Cidara Therapeutics in Q2 2023 and held it in 5 quarters.
Mackenzie Financial's Cidara Therapeutics position peaked at $270K in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.